BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$81.03 USD
-0.69 (-0.84%)
Updated May 10, 2024 04:00 PM ET
After-Market: $81.01 -0.02 (-0.02%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 121 - 140 ( 812 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Pivot: R&D Day Highlights Promise of Early-Stage Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
All Systems Go for VOXZOGO; U.S. Launch Expected By Midto-Late December
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3: Rev Miss Buoyed by Strong FY Guidance; Focus Remains on Regulatory Outcomes
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
BMN 307 Clinical Hold Raises Eyebrows, But No Read Thru to GT Pipeline Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
One Approval Down Another to Go for VOXZOGO; PDUFA Nov. 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department